Products for Research Use Only

Camostat (mesylate)

CAT: 0804-HY-13512-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13512-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase[1][2][3].
CAS Number
59721-29-8
Product Name Alternative
Camostat mesilate; FOY305; FOY-S980
UNSPSC
12352005
Hazard Statement
H315, H319, H335, H400
Target
SARS-CoV; Ser/Thr Protease
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Camostat-mesylate.html
Purity
99.94
Solubility
DMSO : 125 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL
Smiles
O=C(OCC(N(C)C)=O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O
Molecular Formula
C21H26N4O8S
Molecular Weight
494.52
Precautions
H315, H319, H335, H400
References & Citations
[1]Gibo J, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest. 2005;85 (1) :75‐89.|[2]Uno Y. Camostat mesilate therapy for COVID-19 [published online ahead of print, 2020 Apr 29]. Intern Emerg Med. 2020;1‐2.|[3]Coote K, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009;329 (2) :764‐774.|[4]Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76‐84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Am J Physiol Renal Physiol. 2024 Aug 1;327 (2) :F265-F276.|Antiviral Res. 2023 Jun:214:105606.|Biochem Pharmacol. 2023 Jul:213:115617.|Biosaf Health. 2022 Feb;4 (1) :38-44.|Cell Discov. 2021 Dec 14;7 (1) :119.|Cell Prolif. 2025 May 15:e70060.|Cell Rep Med. 2022 Sep 20;3 (9) :100743.|Cell. 2023 Feb 16;186 (4) :850-863.e16.|EBioMedicine. 2023 Sep:95:104753.|Emerg Microbes Infect. 2022 Dec;11 (1) :2275-2287.|Eur J Med Chem. 2021 Nov 15:224:113683.|Eur J Pharmacol. 2022 Mar 15:919:174795.|Eur J Pharmacol. 2023 Jan 5:938:175394.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|J Virol. 2023 May 31;97 (5) :e0032423.|J Virol. 2025 Nov 18:e0127425.|mBio. 2022 Dec 20;13 (6) :e0256622.|Nat Chem Biol. 2022 Sep;18 (9) :963-971.|Nat Commun. 2022 Jul 26;13 (1) :4331.|Nat Commun. 2022 Mar 17;13 (1) :1444.|Nat Commun. 2024 Jul 3;15 (1) :5606.|Nat Commun. 2024 Oct 9;15 (1) :8728.|Nat Commun. 2025 Jul 7;16 (1) :6241.|Nat Microbiol. 2024 Sep;9 (9) :2383-2394.|Nat Microbiol. 2025 Oct 30, 10 (11) :2860-2874.|Nature. 2022 Mar;603 (7902) :693-699.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Proc Natl Acad Sci U S A. 2022 Jan 25;119 (4) :e2117576119.|Res Sq. 2023 Sep 11:rs.3.rs-3220157.|Res Sq. 2024 Nov 21.|Research Square Preprint. 2022 Jan.|Sci Adv. 2023 Jan 20;9 (3) :eadd3867.|Sci China Life Sci. 2025 Oct 24.|Sci Signal. 2024 Aug 20;17 (850) :eadn3785.|Signal Transduct Target Ther. 2022 Mar 11;7 (1) :83.|SSRN. 2020 Jun.|SSRN. 2024 Jan 26.|SSRN. 2024 Jul 11.|Utrecht University. CENTER FOR CELL IMAGING. 2022 Jul.|Viruses. 2022 Feb 8;14 (2) :353.|J Virol. 2025 Aug 11:e0105525.|PLoS Pathog. 2025 Oct 14;21 (10) :e1013593.